Clinical trial
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
NCT00345345 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00345345 |
|---|---|
| Title | Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia |
| Official title | Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | T-LGL Lymphoproliferative Disorders |
| Intervention type | Biological |
| Interventions | Alemtuzumab (Campath) |
| Enrollment | 29 |
| Start date | Oct 17, 2006 |
| Primary completion | Aug 1, 2017 |
| Completion | Oct 27, 2020 |
| First posted | Jun 28, 2006 |
| Last update posted | May 3, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: